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A B S T R A C T
Hyperekplexia or startle disease is a dysfunction of inhibitory glycinergic neurotransmission characterized by an
exaggerated startle in response to trivial tactile or acoustic stimuli. Although rare, this disorder can have serious
consequences, including sudden infant death. One of the most frequent causes of hyperekplexia are mutations in
the SLC6A5 gene, encoding the neuronal glycine transporter 2 (GlyT2), a key component of inhibitory glyci-
nergic presynapses involved in synaptic glycine recycling though sodium and chloride-dependent co-transport.
Most GlyT2 mutations detected so far are recessive, but two dominant missense mutations have been described.
The detailed analysis of these mutations has revealed structural cues on the quaternary structure of GlyT2, and
opens the possibility that novel selective pharmacochaperones have potential therapeutic effects in hyper-
ekplexia.
1. Introduction
Hyperekplexia or "startle disease" (OMIM 149400), is a rare neu-
rological syndrome characterized by pathological alteration of the
brainstem startle reflex controlled by glycinergic neurons. Newborns
display neonatal violent spasms, exaggerated trunk and limb stiffness
and frequent tremor attacks in response to unexpected although trivial
noise or touch stimuli (Hyperekplexia et al., 2007). The disorder is also
called "stiff baby syndrome" since the neonatal hypertonia due to im-
paired motor control precludes the children from executing voluntary
movements. Infants with hyperekplexia have swallowing difficulties,
weaning complications, and are at risk of brain damage or even sudden
death due to apnea episodes unless they are assisted through the Vig-
evano maneuver, which involves flexing of the head and limbs toward
the trunk (Vigevano et al., 1989). Although symptoms often ameliorate
during the first year of life, the exaggerated startle response can persist
into adulthood and the habituation to the startle, or attenuation of the
response after repeated stimulation, is poor or null (Bakker et al.,
2006). Adults suffer disabling motor alterations and recurrent un-
protected falls throughout their entire life (Andermann et al., 1980).
There is not specific treatment for hyperekplexia and the therapy is
directed to prevent hypertonia and startle by potentiating inhibitory
GABAA receptor function with benzodiazepines (Tijssen et al., 1997).
Clonazepam is efficacious against startle, although it is not free of side
effects such as sedation (Thomas et al., 2013).
Brain stem and spinal cord glycinergic pathways control muscle
tone, motor rhythms, spinal reflex responses, and sensory signals (van
den Pol and Gorcs, 1988). The startle reflex produces a brief movement
similar to that of a shock that involves pairs of antagonistic muscles of
the arms, neck, trunk, elbows, hips and knees (Bakker et al., 2006). This
is controlled by brain stem glycinergic interneurons mediating circuits
of reciprocal inhibition that coordinate the contraction and relaxation
of agonist and antagonistic muscle pairs. Inhibitory glycinergic inputs
also regulate motoneuron excitability in the adult and during devel-
opment (Fogarty et al., 2016; Legendre, 2001). Besides, glycine is in-
volved in the processing of auditory information in the cochlear nuclei,
in the complex of the superior olive and in the inferior colliculus
(Wenthold et al., 1987). Inhibitory glycinergic neurons are involved in
the processing of visual information in the retina (Pourcho and Goebel,
1985). In the dorsal horn of the spinal cord, glycine inhibition enables
the suppression of nociceptive signals towards superior brain areas
therefore controlling nociceptive signal transmission (Foster et al.,
2015; Imlach, 2017). The crucial role of glycinergic transmission in
human pain processing has been recently confirmed by the finding that
patients with diagnosed hyperekplexia have increased pain sensitivity
and impaired central pain modulation as compared with control in-
dividuals (Vuilleumier et al., 2018).
At the molecular level, hyperekplexia is a glycinergic synaptopathy
and affects proteins necessary for the proper functioning of the fast
glycine-mediated inhibitory neurotransmission. Glycine released by
glycinergic interneurons activates strychnine-sensitive glycine re-
ceptors (GlyR), which permit chloride influx through the postsynaptic
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membrane leading to hyperpolarization and impairing the propagation
of excitatory postsynaptic potentials (Legendre, 2001; Lynch, 2004).
GlyRs are ligand-gated heteropentameric receptors that in postnatal life
are mainly formed by two α1 channel–forming subunits and three
structural β subunits (Zeilhofer et al., 2018). Within about 250 cases of
hyperekplexia reported in the literature, the most frequent causes are
mutations preventing the function of the glycine receptor affecting
mainly to the α1 subunits (human GLRA1 gene), and with much lower
frequencies to other components of the glycinergic postsynaptic ele-
ment: β subunits (GLRB), collybistin (ARHGEF9) and gephyrin (GPHN),
proteins involved in the postsynaptic organization of glycine receptors
(Harvey et al., 2008).
2. The glycine transporter GlyT2
The second most common causes of hyperekplexia are mutations in
the SLC6A5 gene, encoding the presynaptic glycine transporter GlyT2
(Thomas et al., 2013). The neuronal GlyT2 is a key component of in-
hibitory glycinergic synapses that removes glycine from the synaptic
cleft contributing to the termination of the glycinergic signal together
with its glial counterpart GlyT1 (Aragon and Lopez-Corcuera, 2003).
GlyT2 performs tight Na+-and Cl−-coupled high-affinity glycine co-
transport with a stoichiometry of 3Na+/1Cl−/1glycine thereby
building a stepped gradient of neurotransmitter through the pre-
synaptic plasma membrane (Aragon and Lopez-Corcuera, 2005; Roux
and Supplisson, 2000). As revealed by gene inactivation studies in mice,
loss of GlyT2 function precludes the refilling of synaptic vesicles with
glycine since GlyT2 activity is crucial for supplying substrate to the low-
affinity vesicular glycine transporter VIAAT and hence to preserve
quantal glycine content in synaptic vesicles (Gomeza et al., 2003). The
phenotype of the knock out mice for the GlyT2 gene recapitulated some
of the symptoms of human hyperekplexia including spasticity, rigid
muscle tone, strong spontaneous tremor and a severely impaired
righting reflex and was lethal during the second postnatal week
(Gomeza et al., 2003). These neurological alterations are similar to
those displayed by the spastic, spasmodic and oscillator mouse models
containing mutations in the GlyR α1 subunit gene (Harvey and Yee,
2013). Recently, a spontaneous retrotransposon insertion in mouse
Slc6a5 gene has been shown to cause a related complex phenotype with
handling-induced spasms also lethal within two weeks (Bogdanik et al.,
2012). Together with these evidences, genetic analyses in hyper-
ekplexia patients revealed mutations in the human GlyT2 gene, present
in the short arm of chromosome 11 (Chr 11p15.1–11p15.2) (Morrow
et al., 1998), as the cause of a presynaptic form of the disease (Rees
et al., 2006). There are currently about 30 mutations affecting human
GlyT2 gene (Carta et al., 2012; Eulenburg et al., 2006; Gimenez et al.,
2012; Rees et al., 2006) and several have been found in related con-
genital neurological disorders in dogs (Gill et al., 2011) and cattle
(Charlier et al., 2008). Human SLC6A5 is presently the second major
gene involved in hyperekplexia showing a frequency of mutations of up
to 25%. A recent study showed that patients with GlyT2 gene mutations
were significantly more likely to have recurrent infantile apneas and
developmental delay than those containing GLRA1 mutations (Thomas
et al., 2013).
The SLC6A5 product (GlyT2) belongs to the SLC6 transporter family
that encompasses secondary active transporters energized by the Na+
gradient maintained by the Na+/K+ ATPase, a protein that is physi-
cally and functionally associated with GlyT2 (de Juan-Sanz et al.,
2013b). Cl− is also required for the activity of the eukaryotic family
members. Other SLC6 components include GlyT1, the GABA, and the
monoamine transporters (Broer and Gether, 2012; Drew and Boudker,
2016; Rudnick et al., 2014). SLC6 proteins contain twelve transmem-
brane domains (TM) connected by external (EL) and internal loops (IL)
and cytoplasmic amino and carboxyl-termini. The folding pattern of the
SLC6 transporters was first described in the prokaryotic homologue
LeuTAa (leucine transporter from Aquifex aeolicus) (Yamashita et al.,
2005), and later in the eukaryotic crystals, the Drosophila melanogaster
dopamine transporter (dDAT) (Penmatsa et al., 2013) and the human
serotonin transporter (hSERT) (Coleman et al., 2016). The transporter
TMs shape a cylinder-like structure embedded in the membrane with
central substrate and ion binding sites formed with the contribution of
partially unwound central portions of TM1 and TM6. The main feature
of this folding consists in two topologically inverted structural repeats
of five TMs each, which intertwine to form two four-TM bundles: one
mobile bundle (core) and a more static bundle (scaffold) (Rudnick
et al., 2014). During the transport cycle, the protein binds the substrate
and ions in one side of the membrane and undergoes conformational
changes that let the two bundles rock one against the other releasing
substrate and ions to the opposite side (Jardetzky, 1966). LeuTAa
translocation cycle requires two sodium ions. The two sodium-binding
sites are conserved within the SLC6 family and some of their functional
roles were unveiled: tight substrate coupling for Na1 (Penmatsa and
Gouaux, 2014), and stabilization of the outward-facing conformation
for Na2 (Claxton et al., 2010).
Based on the bacterial LeuTAa structure, 3D models for glycine
transporters were generated and molecular dynamics simulations and
mutant analysis confirmed the conservation of the two sodium sites
(Perez-Siles et al., 2011). By studying the differential sensitivity of
GlyT2 and GlyT1 to lithium ion it was found that Na1 is a high affinity,
high selectivity site whereas Na2 is a lower affinity, lower selectivity
site where lithium can bind (Perez-Siles et al., 2011, 2012). Recently,
the location of the third sodium site in GlyT2 was proposed and the
features of this site and how it is coupled to energize the transport of
glycine awaits further investigation (Subramanian et al., 2016). An
additional sodium-binding region present in the extracellular vestibule
of GlyT2 but absent in GlyT1 was identified indicating a role in cation
guiding of the outward-facing cavity of GlyT2 (Perez-Siles et al., 2012;
Zomot et al., 2015). The crystal structure of the two eukaryotic SLC6
members solved so far, dDAT and hSERT, showed differences with the
prokaryotic model (Coleman et al., 2016; Penmatsa et al., 2013). The
presence of bound cholesterol in both crystals, although in different
locations, was particularly relevant for a lipid-raft associated trans-
porter as GlyT2 (Coleman et al., 2016; Nunez et al., 2008; Penmatsa
et al., 2013). Recently, a cholesterol site involving TM1a, TM5 and TM7
able to immobilize the cytoplasmic portion of TM5 and to stabilize the
transporter in an outward-facing conformation was found to be the
preferred binding site for some SLC6 proteins (Zeppelin et al., 2018).
The eukaryotic structures gave clues for the first time on the arrange-
ment of large external loops: EL2 and EL4, which may provide sub-
stantial information for the binding site of some GlyT2 inhibitors
(Vandenberg et al., 2016). An interaction of the carboxyl-terminal helix
and the IL1-TM1a essential for the folding and the function of the
transporters was also evidenced (El-Kasaby et al., 2010; Penmatsa et al.,
2013). Some novel hints on the eukaryote dimerization interface arise
from the differential conformation of the TM12 where a proline residue
makes the C-terminal half of the helix to protrude outside the monomer
(Coleman and Gouaux, 2018). Presently, GlyT2 models based in dDAT
have being developed, and will help to investigate selected missense
hyperekplexia-associated mutations on critical residues involved in
transporter function or trafficking (Carland et al., 2018).
3. GlyT2 biogenesis
The synthesis of GlyT2 takes place in ribosomes associated to the
endoplasmic reticulum (ER). The ER is the organelle where proteins are
folded and maturate under a stringent quality control that warrants ER
emergent molecules have the proper structure (Ellgaard and Helenius,
2003). Membrane protein synthesis begins with the co-translational
translocation of the nascent peptide to the ER membrane and its lateral
inclusion in the membrane in a correct topological orientation (Guna
and Hegde, 2018). The ER lumen contains optimal composition: oxi-
dizing conditions, available ATP, pH neutral, high concentration of
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calcium and optimized ionic environment for protein folding, disulfide
bond formation and N-glycosylation. Besides, RE lumen is filled with
molecular chaperones, thiol oxidoreductases, prolyl isomerases, and N-
linked glycan–modifying enzymes and will include emergent protein
domains destined to the extracellular milieu, including N-glycosilated
regions (Barlowe and Helenius, 2016). Four asparagines in GlyT2 EL2
receive preassembled glycan chains generating an immature under-
glycosylated GlyT2 precursor that will acquire complex N-glycosylation
along the secretory pathway. The glycosylation helps to stabilize pro-
tein folding permitting the acquisition of the desired biophysical
properties (Martinez-Maza et al., 2001; Nunez and Aragon, 1994).
Other posttranslational modifications such as acylation may also be
inserted in the ER (Shipston, 2014). Correct transporter folding requires
interaction with several ER chaperones, some of which recognize and
shield hydrophobic TMs to assist folding such as the lectin calnexin
(CNX). The biogenesis of the transporter in cells expressing GlyT2 can
be modulated by the concentrations of this chaperone that controls the
quality of the immature GlyT2 precursor and therefore the amount of
active transporter. In cells expressing GlyT2, transporter accumulation
and transport activity were attenuated by siRNA-mediated CNX
knockdown and enhanced by CNX overexpression (Arribas-Gonzalez
et al., 2013). The transient binding of CNX to the immature GlyT2 in the
RE is mediated by glycan and polypeptide-based interactions through
which the chaperone discriminates between different GlyT2 folding
states. In this way, the sequential site directed removal of selected N-
glycans although reduced chaperone binding also increased transporter
unfolding. These conditions exert opposite actions on the binding to the
chaperone so that a GlyT2 mutant lacking all four N-glycan acceptor
sites, which exhibits anomalous folding, has also long lasting interac-
tion with CNX. The highest contribution to transporter misfolding takes
place after mutagenesis of Asn-366, suggesting high stabilizing role for
the glycan linked to Asn-366. Moreover, the modest glycine transport of
the mutant lacking all four N-glycan acceptor sites could be rescued by
CNX overexpression to a higher level than its plasma membrane ex-
pression indicating CNX can exert genuine chaperone activity on GlyT2
independent of its lectin ability.
For ER exit, proteins are loaded into COPII transport vesicles that
assemble in ER exit sites (ERES). The COPII coat complex contains an
inner shell (Sec23/Sec24 complex) that sorts cargoes and an outer cage
(Sec13/Sec31 complex) that leads to coat polymerization and induces
membrane curvature for budding (Miller et al., 2003). The four Sec24
(A, B, C, D) variants are mainly responsible for efficient cargo loading
into the vesicles by binding either directly or through adaptors to ex-
port signals and motifs in fully folded and oligomerized proteins. These
motifs may not be available until folding and assembly are completed.
Incompletely folded cargo proteins are actively removed from ERES
(Barlowe and Helenius, 2016). The SLC6 transporters contain an ER
export signal in the carboxyl terminus that supports the binding to the
Sec24 adaptor (Arribas-Gonzalez et al., 2015; Farhan et al., 2004).
GlyT2 seems to share a RL (X8)D motif in the C-terminus with the re-
lated GlyT1 that may support the interaction with Sec24D, although
additional export signals may be involved (Fernandez-Sanchez et al.,
2008). In GlyT2 the removal or mutagenesis of this region prevents ER
export and Sec24D interaction (Arribas-Gonzalez et al., 2015;
Fernandez-Sanchez et al., 2008). The RL motif is also conserved in
GAT1 and it mediates the binding to Sec24D and transporter con-
centrative ER export (Farhan et al., 2007). Although GAT1 oligomeric
assembly seems not to be required for the interaction with Sec24D,
oligomerization of transporters may bring together several ER COPII-
binding motifs, thereby increasing the efficiency of ER export. Thus, the
“oligomerization hypothesis” for SLC6 transporters claims oligomer-
ization supports efficient recruitment of COPII components and there-
fore is required for ER export (Farhan et al., 2007; Sitte and Freissmuth,
2003) (Freissmuth et al., 2018). CNX assistance to GlyT2 folding sug-
gests GlyT2 bound to CNX is in a monomeric state and CNX release
permits the transporters to form oligomers that can be concentrated in
ERES by interaction with Sec24. The in vivo GlyT2 oligomeric assembly
is presently unknown. Previous data in the literature found GlyT2 di-
mers were generated under nonnative conditions after transporter
crosslinking (Bartholomaus et al., 2008). However, it was after the
discovery of GlyT2 dominant hyperekplexia mutations that robust
evidences for the in vivo occurrence of GlyT2 oligomers were obtained
(see below) (Arribas-Gonzalez et al., 2015; Gimenez et al., 2012).
In neurons, the mature GlyT2 transporter traffics to the plasma
membrane incorporated into small vesicles containing synaptic vesicle
protein components such as synaptophysin, or the vesicular inhibitory
amino acid transporter VIAAT but no other protein involved in
GABAergic transmission (Nunez et al., 2009). The transporter protein is
concentrated at presynaptic elements by interaction with syntenin-1
through a PDZ motif located in GlyT2 C-terminal end (Armsen et al.,
2007). GlyT2 is delivered into neuronal plasma membrane lipid-rafts,
whose components cholesterol and sphingolipids provide the most fa-
vorable environment for optimal transport function (Nunez et al.,
2008). Membrane lipids are also stringent regulators of functional in-
teractions of GlyT2 with other plasma membrane transporters such as
the neuronal isoforms of Na+/K+-ATPase (de Juan-Sanz et al., 2013b),
the neuronal plasma membrane Ca2+-ATPase (PMCA), and the Na+/
Ca2+-exchanger 1 (NCX1) (de Juan-Sanz et al., 2014). The activities of
these transporters are necessary for optimal GlyT2 activity in the pre-
synapse and this modulation depends on lipid raft integrity. These in-
teracting partners are included in a functional unit proposed to main-
tain local cation gradient homeostasis after neuronal (and GlyT2)
intense activity. GlyT2 endocytosis is dependent on ubiquitination of C-
terminal lysines, what tags the transporter either for constitutive re-
cycling into Rab11-containing vesicles or for lysosomal degradation (de
Juan-Sanz et al., 2011, 2013a). Modulation of GlyT2 trafficking is
achieved by several signals in a process also dependent on GlyT2 ubi-
quitination (de Juan-Sanz et al., 2011).
4. GlyT2 hyperekplexia-associated mutations
Several structural and functional properties of GlyT2 have been
reported to be altered or could be potentially affected in hyperekplexia
patients. Although the majority of GlyT2 mutations associated to hy-
perekplexia are loss of function and may reduce the glycine supply to
the presynaptic terminal impairing the glycinergic neurotransmission,
there are GlyT2 mutants that maintain residual or even significant ac-
tivity and could affect other aspects of GlyT2 physiology. A high pro-
portion of changes found in GlyT2 are nonsense and frameshift muta-
tions (W151X, R191X, Y297X, Y377X, R439X, V432F + fs97, Q630X,
P108L + fs25, L198R + fs123, S489F + fs39, I665K + fs1), which
truncate the transporters and cause retention of the misfolded inactive
protein in the ER. Others are missense mutations affecting residues with
crucial roles for the catalytic transport activity such as the sodium
binding sites (N509S, A275T), the Cl− site (S513I), or the glycine site
(W482R). Some are proposed to affect conformational changes needed
for the translocation cycle (L237P, L243T, T425M, Y491C, F547S,
Y656H, G657A) (Carta et al., 2012; Eulenburg et al., 2006; Rees et al.,
2006). The inheritance of GlyT2 mutations so far found in hyper-
ekplexia patients is mostly recessive or in compound heterozygous
state. Though, two dominant missense mutations have been described,
whose pathogenic mechanisms have been studied by our group. One of
such mutations was found in eight patients from Spain and the United
Kingdom after sequencing the 16 exons of the SLC6A5 gene of 204
individuals who had tested negative for mutations in GLRA1 (5q33.1)
and GLRB (4q32.1) (Gimenez et al., 2012). A single nucleotide change
in exon 15 was found in heterozygosis that caused dominant in-
heritance and significant variation in clinical presentation. The change
introduced a cysteine in TM11, in the outer face of the protein, instead
of a conserved tyrosine residue (Y705C). The mutant expressed in
heterologous cells and primary neurons was active, and maintained
about 60% glycine transport and surface expression that could be
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rescued by treatment with reducing agents. By mutagenesis of several
endogenous cysteine residues in the Y705C background and systematic
assay of reducing agent rescue, it was found that the introduced cy-
steine aberrantly interacts and disrupts an endogenous disulfide bond
between Cys-311 and Cys-320 in EL2 of GlyT2. According to the re-
levant role of this loop in transporter structure and function recently
confirmed in the hSERT crystal (Coleman et al., 2016), this interference
hinders transporter progression to the plasma membrane and inhibits
glycine transport. It is presently unknown whether this feature is re-
lated to the dominant inheritance of the mutation since it is recessive in
heterologous cells. However, in the same heterologous system the
mutant shows altered sensitivity to protons and zinc that appears even
when wild-type and mutant are co-expressed, suggesting it is dominant
in heterozygosity. Accordingly, the substitution of Y705 by an acidic
amino acid such as glutamate or aspartate strongly impaired GlyT2
transport activity. The more acidic character of cysteine as compared to
tyrosine might trigger the dysregulation. Further analysis in neural
preparations may unveil to which extent this altered regulation impairs
glycinergic neurotransmission (Chen et al., 2004; Hirzel et al., 2006;
Krishtal et al., 1987).
There is another dominant missense mutation found in hyper-
ekplexia patients that substitutes a serine in TM7 by an arginine
(S510R) what prevents mutant maturation (Rees et al., 2006). The
mutant blocks the arrival of the transporter to the surface exerting a
dominant-negative effect that impairs GlyT2 intracellular trafficking.
An extensive analysis of the pathogenic mechanisms of this mutant
using the rat sequence, S512R (equivalent to the human mutation
S510R), was performed and it was found it is a folding-defective mutant
that does not produce a mature transporter but rather the immature
transporter is retained in the ER (Arribas-Gonzalez et al., 2015). The
presence of an arginine but not the removal of serine-512 provokes the
misfolding as proven by multiple mutagenesis analysis in this and
contiguous positions including serine-513, a residue substituted by an
isoleucine in some hyperekplexia patients with recessive inheritance.
The glycosidase sensitivity of S512R indicates mutant maturation is
arrested after receiving the first preassembled glycans. Co-translation-
ally trimmed glycans by ER glucosidases generate monoglucosylated
chains that support binding to CNX (Hammond et al., 1994). Therefore,
S512R is a preferred substrate for the chaperone and has enhanced
association to CNX as compared to wild type. In addition, the interac-
tion of the mutant with the adaptor protein Sec24D, responsible for
COPII vesicle cargo selection is poor and this impedes mutant exit from
the ER. S512R mutant subunits form heteroligomers with wild-type
GlyT2. Since the stability of these mixed oligomers is higher than GlyT2
homoligomers, wild-type is retained in the ER and the mutant exerts a
dominant-negative effect on GlyT2 traffic. Interestingly, CNX over-
expression can rescue the dominant-negative effect by increasing the
amount of wild-type GlyT2 that reaches the plasma membrane and
attenuating the interaction between wild-type and mutant transporters.
Reminiscent of the chaperoning function of proteinaceous chaperones
as CNX, the effect of chemical chaperones in the rescue of GlyT2 was
analyzed. Several nonselective compounds belonging to the main
classes of chemical chaperones were proven and some were able to
rescue the wild-type transporter from the dominant negative effect of
S512R. The FDA approved compound 4-phenylbutyrate (PBA) pro-
moted significant rescue comparable to that of CNX. It restored both
membrane expression and glycine transport of the active GlyT2 co-ex-
pressed with the mutant in heterologous cells and primary neurons.
PBA is an interesting compound since it can pass across the blood–brain
barrier and it has been implicated as protective agent in some neural
diseases (Ozcan et al., 2009). It is proposed that the overexpression of
CNX or the treatment with PBA can dissociate the wild-type-mutant
heteroligomers retained in the ER and this would send the mutant to
ER-associated degradation and permit wild-type molecules to reach the
plasma membrane and relieve the dominant-negative effect. These re-
sults support the possibility that novel selective pharmacopherones may
have potential therapeutic effects in hyperekplexia patients. More
specific pharmacopherones may be useful in hyperekplexia not only for
the treatment of newborns holding GlyT2 mutations affecting trans-
porter trafficking but also to help the relief of the increased pain sen-
sation and impaired central pain modulation the patients with diag-
nosed hyperekplexia have as compared with control individuals. This
may importantly enlarge the usefulness of the obtained medicines since
they could be used during lifetime by the adult hyperekplexia patients
and improve their quality of life.
The discovery of GlyT2 dominant hyperekplexia mutations has
provided robust evidences for the in vivo occurrence of GlyT2 oligo-
mers (Arribas-Gonzalez et al., 2015; Gimenez et al., 2012). The pa-
thogenic mechanisms of the two dominant mutations found in hyper-
ekplexia patients rely on the formation of heteroligomers carrying wild
type and mutant protomers. Therefore they are the first in vivo evi-
dence of the quaternary structure of GlyT2. The dominant-negative
effect of GlyT2 trafficking exerted by S510R mutant is due to the for-
mation of heteroligomers in the ER. Although this was formerly ac-
cepted to be a general requisite for the incorporation into COPII vesicles
and the ER exit of SLC6 transporters (“the oligomerization hypothesis”,
(Sitte and Freissmuth, 2003), this was not previously demonstrated for
GlyT2. The arrest exerted by S512R on GlyT2 trafficking is dependent,
as expected, on the dose of the mutant co-expressed with the wild-type
and can be quantified assuming the basic element of the transporter
quaternary structure is a dimer (Coleman et al., 2016; Penmatsa et al.,
2013). In SERT, it has been proposed that oligomer formation is in-
itiated in the ER but the ER oligomers are mobile and can exchange
protomers in contrast to the plasma membrane oligomers, which are
fixed due to the association with phosphatidylinositol-4,5-bispho-
sphate/PIP2 (Anderluh et al., 2017). For the dominant-negative action
of S512R, the remaining transport activity detected when wild-type and
mutant were co-expressed was higher than expected assuming all the
dimers containing mutant protomers -alone or in combination-were
inactive (retained) (Arribas-Gonzalez et al., 2015). The stochastic as-
sociation of wild-type and S512R mutant would result in residual
transport activity of about 25% assuming all wild-type molecules that
interact with S512R are retained (Fig. 1). Higher order oligomers would
yield more depressed residual transport activity (i.e. about 4.5% if it
would be a tetramer). This condition was described for the coexpression
of wild-type norepinephrine transporter NET and a dominant negative
mutant found in familial orthostatic intolerance (Farhan et al., 2006;
Hahn et al., 2003). However, the measured residual transport activity of
wild-type GlyT2 and S512R was around 45–50%. Since the actual ac-
tivity of the wild-type/S512R heteromers is not known, this level of
residual activity could be reached assuming two possible scenarios: 1)
the S512R mutation is not dominant and wild-type/S512R mutants are
50% active. About 40% predicted activity could also be obtained as-
suming tetrameric structure of 50% active dimers. These conditions are
very unlucky as we determined the interaction strength of wild-type/
S512R heteromers is higher than that of wild-type homomers sup-
porting a dominant-negative action of the mutant. 2) The second con-
jecture that can be posed to explain 45–50% residual activity for the
coexpression is the wild-type/S512R heteromers display glycine trans-
port below 50% but above 25%. This could be compatible with a non-
permanent arrest of wild-type GlyT2 due to S512R association that can
be relieved through monomer exchange. This agrees with a mobile
fraction of oligomers in the ER as proposed (Anderluh et al., 2017).
Furthermore, the rescue of the dominant-negative effect by CNX over-
expression or PBA treatment seems more easily explained with a mobile
fraction of ER oligomers. On the other hand, the dominance of the
Y705C mutant suggests GlyT2 heteroligomers carrying wild type and
mutant protomers reach the plasma membrane. The phenotype of the
transporters co-expressed in COS7 cells seems to be quantitatively si-
milar to the phenotype of the Y705C mutant expressed by itself, and
presumably forming homoligomers what may sustain the hypothesis of
fixed oligomers at the plasma membrane. The investigation of GlyT2
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quaternary structure will unveil the correct oligomer assembly of the
transporter and will provide valuable information for the study of
mutations associated to hyperekplexia.
5. Conclusion
This short review contains the recent data on GlyT2 mutations in-
volved in hyperekplexia. The neuronal GlyT2 is a crucial protein for
glycine recycling in inhibitory glycinergic synapses and transporter loss
of function abolishes glycinergic neurotransmission. Recessive muta-
tions in GlyT2 gene (SLC6A5) are the second most common causes of
hyperekplexia. The pathogenic mechanisms of two dominant mutations
have been analyzed revealing different aspects of GlyT2 function can be
affected in hyperekplexia. Dominance of two mutations supports the
role of the quaternary structure of the transporter in physio-patholo-
gical aspects involving GlyT2.
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